Page last updated: 2024-10-28

hypericin and Diabetes Mellitus, Type 2

hypericin has been researched along with Diabetes Mellitus, Type 2 in 2 studies

Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

Research Excerpts

ExcerptRelevanceReference
"Alzheimer's disease (AD) and type 2 diabetes (T2D) are two of the most common diseases in elderly population and they have a high rate of comorbidity."1.91Hypericin as a potential drug for treating Alzheimer's disease and type 2 diabetes with a view to drug repositioning. ( Gao, LH; Ma, QH; Wang, J; Yan, F; Yuan, X, 2023)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Yuan, X1
Yan, F1
Gao, LH1
Ma, QH1
Wang, J1
Liang, C1
Hao, F1
Yao, X1
Qiu, Y1
Liu, L1
Wang, S1
Yu, C1
Song, Z1
Bao, Y1
Yi, J1
Huang, Y1
Wu, Y1
Zheng, L1
Sun, Y1
Wang, G1
Yang, X1
Yang, S1
Sun, L1
Li, Y1

Other Studies

2 other studies available for hypericin and Diabetes Mellitus, Type 2

ArticleYear
Hypericin as a potential drug for treating Alzheimer's disease and type 2 diabetes with a view to drug repositioning.
    CNS neuroscience & therapeutics, 2023, Volume: 29, Issue:11

    Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Diabetes Mellitus, Type 2; Drug Repositioning; Human

2023
Hypericin maintians PDX1 expression via the Erk pathway and protects islet β-cells against glucotoxicity and lipotoxicity.
    International journal of biological sciences, 2019, Volume: 15, Issue:7

    Topics: Animals; Anthracenes; Antioxidants; Apoptosis; Cell Line; Cell Survival; Diabetes Mellitus, Type 2;

2019